Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Trop Med Parasitol ; 105(8): 537-47, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22325813

RESUMO

Onchocerciasis, lymphatic filariasis (LF), schistosomiasis and soil transmitted, helminthiasis (STH) are all co-endemic in Nigeria. Annual mass drug administration (MDA) with ivermectin (for onchocerciasis), albendazole (for STH and with ivermectin for LF) and praziquantel (for schistosomiasis) is the WHO-recommended treatment strategy for preventive chemotherapy. Separate delivery rounds for distribution of these drugs have been the usual approach to MDA. All three drugs, however, have now been shown to be clinically and programmatically safe for co-administration with what has come to be known as triple drug administration (TDA). We examined the cost savings of converting from separate delivery rounds to TDA in two states in Nigeria. In 2008, eight local government areas received a single round of ivermectin with albendazole followed at least 1 week later by a single round of praziquantel to school-aged children. The following year, a single round was administered with TDA. The number of treated individuals was essentially unchanged during both years (1,301,864 in 2008 and 1,297,509 in 2009) and no change in adverse events was reported. The total programmatic costs for the MDA, not including drug and overhead costs, reduced by 41% from $123,624 to $72,870. Cost savings were limited in larger populations due to economies of scale. TDA is recommended for mature MDA.


Assuntos
Antiparasitários/administração & dosagem , Doenças Negligenciadas/prevenção & controle , Doenças Parasitárias/prevenção & controle , Adolescente , Adulto , Albendazol/administração & dosagem , Albendazol/efeitos adversos , Albendazol/economia , Albendazol/uso terapêutico , Antiparasitários/efeitos adversos , Antiparasitários/economia , Antiparasitários/uso terapêutico , Criança , Análise Custo-Benefício , Esquema de Medicação , Custos de Medicamentos/estatística & dados numéricos , Quimioterapia Combinada , Uso de Medicamentos/estatística & dados numéricos , Custos de Cuidados de Saúde/estatística & dados numéricos , Humanos , Ivermectina/administração & dosagem , Ivermectina/efeitos adversos , Ivermectina/economia , Ivermectina/uso terapêutico , Doenças Negligenciadas/economia , Nigéria , Doenças Parasitárias/economia , Praziquantel/administração & dosagem , Praziquantel/efeitos adversos , Praziquantel/economia , Praziquantel/uso terapêutico , Adulto Jovem
3.
Minerva Med ; 93(4): 309-13, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12207201

RESUMO

Thrombotic disease is one of the most relevant clinical problems for morbility and mortality. We can differentiate congenital and acquired forms. In this short communication we describe 1 case observed by us that seems interesting for the association of a congenital and acquired form [Protein S deficiency and inflammatory bowel disease (IBD)] and for the dramatic events suffered before receiving a complete diagnosis and therapy, indicating the importance of recollection of information from the patients, starting from anamnestic data.


Assuntos
Doença de Crohn/complicações , Deficiência de Proteína S/complicações , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA